Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
117 hedge funds and large institutions have $679M invested in Accelerate Diagnostics in 2019 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 37 increasing their positions, 25 reducing their positions, and 12 closing their positions.
50% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 12
48% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 25
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
17% more capital invested
Capital invested by funds: $580M → $679M (+$98.9M)
3% more funds holding
Funds holding: 114 → 117 (+3)
8% more call options, than puts
Call options by funds: $10.2M | Put options by funds: $9.47M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Axa
Paris,
France
|
+$25.9M |
| 2 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
+$8.02M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.12M |
| 4 |
BlackRock
New York
|
+$5.23M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$4.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
-$8.56M |
| 2 |
CCM
Cadian Capital Management
New York
|
-$5.5M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.17M |
| 4 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
-$1.07M |
| 5 |
AG
Artal Group
Luxembourg
|
-$978K |
AXDX Hedge Fund Activity: Q2 2019 in Review
117 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q2 2019, worth a combined $679M — up 17% from $580M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new AXDX positions and 12 closed out — a net gain of 6 holders — while 37 added to existing stakes and 25 trimmed.
The largest buyer was Axa, adding an estimated $25.9M. The largest seller was Amundi Asset Management US, cutting an estimated $8.56M.
- 117 institutional investors held Accelerate Diagnostics (AXDX) as of Q2 2019, up from 114 in Q1 2019.
- Funds reported $679M of Accelerate Diagnostics stock for Q2 2019, up 17% quarter-over-quarter.
- 18 funds opened new Accelerate Diagnostics positions in Q2 2019 and 12 closed out, a net change of +6 holders.
- The largest Accelerate Diagnostics buyer in Q2 2019 was Axa, an estimated $25.9M added.
- The largest Accelerate Diagnostics seller in Q2 2019 was Amundi Asset Management US, an estimated $8.56M sold.
Based on aggregated 13F filings for Q2 2019.